The OncLive Insider app is live!CME Opportunities

The OncLive Insider app is live!CME Opportunities

View More Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Ovarian Cancer Prostate Cancer Melanoma & Skin Cancer MCL MPN CAR T-cell Therapy Chronic Lymphocytic Leukemia Gynecologic Oncology Hematologic Oncology Immuno-Oncology Multiple Myeloma Urothelial Cancer

Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Ovarian Cancer Prostate Cancer Melanoma & Skin Cancer MCL MPN CAR T-cell Therapy Chronic Lymphocytic Leukemia Gynecologic Oncology Hematologic Oncology Immuno-Oncology Multiple Myeloma Urothelial Cancer

All Oncology News

OncLive News Network®

Insights MedNews Week OncChats OncLive News Network®OncLive TV Peer Exchange Podcasts Rapid Readouts

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Giants of Cancer Care

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Giants of Cancer Care CME/CE Scientific Interchanges State of the Science Summit / IPC National Fellows Forum Webinars

Partners Publications

Consensus Viewpoints

Interactive Tools

Consensus Viewpoints OncLive App Interactive Tools Sponsored

Biomarker Consortium Subscribe

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

© 2025 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

The OncLive Insider app is live!
CME Opportunities

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

OncLive SOSS

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Advances in Treatment for ALK-Positive NSCLC

EP. 1: Targeted TKIs Used for Treatment of ALK-Positive NSCLC

July 12th 2019

EP. 2: ALK-Positive NSCLC: ALEX Trial

July 12th 2019

EP. 3: ALK-Positive NSCLC: ASCEND-4 Trial

July 12th 2019

EP. 4: Factors to Consider in Choosing ALK TKIs in Frontline Setting

July 12th 2019

EP. 5: ALTA-1L: Brigatinib Versus Crizotinib for ALK+ NSCLC

July 12th 2019

EP. 6: Progression in ALK+ NSCLC After Frontline Therapy

July 12th 2019

EP. 7: Resistance to ALK TKIs

July 12th 2019

EP. 8: Second-Line Treatment for ALK-Positive NSCLC

July 12th 2019

EP. 9: ALTA II: Brigatinib in Crizotinib-Resistant ALK+ NSCLC

July 12th 2019

EP. 10: Available Choices in ALK+ Therapy and Rationale for Selection

July 12th 2019

<
1
2
>

x